An investigation into the structural determinants of cannabinoid receptor ligand efficacy
- 1 April 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (7) , 1575-1584
- https://doi.org/10.1038/sj.bjp.0702469
Abstract
1. A number of side-chain analogues of delta8-THC were tested in GTPgammaS binding assay in rat cerebellar membranes. O-1125, a saturated side-chain compound stimulated GTPgammaS binding with an Emax of 165.0%, and an EC50 of 17.4 nM. 2. O-1236, O-1237 and O-1238, three-enyl derivatives containing a cis carbon-carbon double bond in the side-chain, stimulated GTPgammaS binding, acting as partial agonists with Emax values ranging from 51.3-87.5% and EC50 values between 4.4 and 29.7 nM. 3. The stimulatory effects of O-1125, O-1236, O-1237 and O-1238 on GTPgammaS binding were antagonized by the CB1 receptor antagonist SR 141716A. The K(B) values obtained ranged from 0.11-0.21 mM, suggesting an action at CB1 receptors. 4. Five-ynyl derivatives (O-584, O-806, O-823, O-1176 and O-1184), each containing a carbon-carbon triple bond in the side-chain, did not stimulate GTPgammaS binding and were tested as potential cannabinoid receptor antagonists. 5. Each -ynyl compound antagonized the stimulatory effects of four cannabinoid receptor agonists on GTPgammaS binding. The K(B) values obtained, all found to be in the nanomolar range, did not differ between agonists or from cerebellar binding affinity. 6. In conclusion, alterations of the side-chain of the classical cannabinoid structure may exert a large influence on affinity and efficacy at the CB1 receptor. 7. Furthermore, this study confirms the ability of the GTPgammaS binding assay to assess discrete differences in ligand efficacies which potentially may not be observed using alternative functional assays, thus providing a unique tool for the assessment of the molecular mechanisms underlying ligand efficacies.Keywords
This publication has 22 references indexed in Scilit:
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- Pharmacology of cannabinoid CB1 and CB2 receptorsPharmacology & Therapeutics, 1997
- Agonist-antagonist characterization of 6′-cyanohex-2′-yne-Δ8-tetrahydrocannabinol in two isolated tissue preparationsEuropean Journal of Pharmacology, 1996
- Cannabinoid receptor stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding in rat brain membranesLife Sciences, 1996
- Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brainLife Sciences, 1996
- A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferensEuropean Journal of Pharmacology, 1995
- Differential Regulation by Guanine Nucleotides of Opiate Agonist and Antagonist Receptor InteractionsJournal of Neurochemistry, 1980
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973